Literature DB >> 26028029

Prostate-specific G-protein-coupled receptor collaborates with loss of PTEN to promote prostate cancer progression.

M Rodriguez1, S Siwko1, L Zeng1, J Li2, Z Yi2, M Liu1,2.   

Abstract

Among frequent events in prostate cancer are loss of the tumor-suppressor phosphatase and tensin homologue (PTEN) and overexpression of prostate-specific G-protein-coupled receptor (PSGR), but the potential tumorigenic synergy between these lesions is unknown. Here, we report a new mouse model (PSGR-Pten(Δ/Δ)) combining prostate-specific loss of Pten with probasin promoter-driven PSGR overexpression. By 12 months PSGR-Pten(Δ/Δ) mice developed invasive prostate tumors featuring Akt activation and extensive inflammatory cell infiltration. PSGR-Pten(Δ/Δ) tumors exhibited E-cadherin loss and increased stromal androgen receptor (AR) expression. PSGR overexpression increased LNCaP proliferation, whereas PSGR short hairpin RNA knockdown inhibited proliferation and migration. In conclusion, we demonstrate that PSGR overexpression synergizes with loss of PTEN to accelerate prostate cancer development, and present a novel bigenic mouse model that mimics the human condition, where both PSGR overexpression and loss of PTEN occur concordantly in the majority of advanced prostate cancers, yielding an environment more relevant to studying human prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26028029      PMCID: PMC4683109          DOI: 10.1038/onc.2015.170

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  41 in total

Review 1.  Epidemiological investigation of prostate cancer.

Authors:  Graham G Giles
Journal:  Methods Mol Med       Date:  2003

Review 2.  Molecular genetics of prostate cancer: new prospects for old challenges.

Authors:  Michael M Shen; Cory Abate-Shen
Journal:  Genes Dev       Date:  2010-09-15       Impact factor: 11.361

3.  Increased expression of prostate-specific G-protein-coupled receptor in human prostate intraepithelial neoplasia and prostate cancers.

Authors:  Jinsheng Weng; Jianghua Wang; Yi Cai; Lewis Joe Stafford; Dianne Mitchell; Michael Ittmann; Mingyao Liu
Journal:  Int J Cancer       Date:  2005-02-20       Impact factor: 7.396

4.  Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial.

Authors:  Bora Gurel; M Scott Lucia; Ian M Thompson; Phyllis J Goodman; Catherine M Tangen; Alan R Kristal; Howard L Parnes; Ashraful Hoque; Scott M Lippman; Siobhan Sutcliffe; Sarah B Peskoe; Charles G Drake; William G Nelson; Angelo M De Marzo; Elizabeth A Platz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-04-18       Impact factor: 4.254

5.  Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome.

Authors:  Maisa Yoshimoto; Anthony M Joshua; Isabela W Cunha; Renata A Coudry; Francisco P Fonseca; Olga Ludkovski; Maria Zielenska; Fernando A Soares; Jeremy A Squire
Journal:  Mod Pathol       Date:  2008-05-23       Impact factor: 7.842

6.  Targeting the stromal androgen receptor in primary prostate tumors at earlier stages.

Authors:  Yuanjie Niu; Saleh Altuwaijri; Shuyuan Yeh; Kuo-Pao Lai; Shengqiang Yu; Kuang-Hsiang Chuang; Shu-Pin Huang; Henry Lardy; Chawnshang Chang
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-22       Impact factor: 11.205

7.  Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer.

Authors:  Shunyou Wang; Jing Gao; Qunying Lei; Nora Rozengurt; Colin Pritchard; Jing Jiao; George V Thomas; Gang Li; Pradip Roy-Burman; Peter S Nelson; Xin Liu; Hong Wu
Journal:  Cancer Cell       Date:  2003-09       Impact factor: 31.743

8.  Promotion of cancer cell invasiveness and metastasis emergence caused by olfactory receptor stimulation.

Authors:  Guenhaël Sanz; Isabelle Leray; Aurélie Dewaele; Julien Sobilo; Stéphanie Lerondel; Stéphan Bouet; Denise Grébert; Régine Monnerie; Edith Pajot-Augy; Lluis M Mir
Journal:  PLoS One       Date:  2014-01-08       Impact factor: 3.240

9.  Pten dose dictates cancer progression in the prostate.

Authors:  Lloyd C Trotman; Masaru Niki; Zohar A Dotan; Jason A Koutcher; Antonio Di Cristofano; Andrew Xiao; Alan S Khoo; Pradip Roy-Burman; Norman M Greenberg; Terry Van Dyke; Carlos Cordon-Cardo; Pier Paolo Pandolfi
Journal:  PLoS Biol       Date:  2003-10-27       Impact factor: 8.029

10.  FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome.

Authors:  M Yoshimoto; I W Cunha; R A Coudry; F P Fonseca; C H Torres; F A Soares; J A Squire
Journal:  Br J Cancer       Date:  2007-08-14       Impact factor: 7.640

View more
  16 in total

1.  Prostate cancer: PTEN loss and PSGR overexpression promote cancer progression.

Authors:  Louise Stone
Journal:  Nat Rev Urol       Date:  2015-06-16       Impact factor: 14.432

Review 2.  Role of Short Chain Fatty Acid Receptors in Intestinal Physiology and Pathophysiology.

Authors:  Medha Priyadarshini; Kumar U Kotlo; Pradeep K Dudeja; Brian T Layden
Journal:  Compr Physiol       Date:  2018-06-18       Impact factor: 9.090

3.  Identification of shared and unique susceptibility pathways among cancers of the lung, breast, and prostate from genome-wide association studies and tissue-specific protein interactions.

Authors:  David C Qian; Jinyoung Byun; Younghun Han; Casey S Greene; John K Field; Rayjean J Hung; Yonathan Brhane; John R Mclaughlin; Gordon Fehringer; Maria Teresa Landi; Albert Rosenberger; Heike Bickeböller; Jyoti Malhotra; Angela Risch; Joachim Heinrich; David J Hunter; Brian E Henderson; Christopher A Haiman; Fredrick R Schumacher; Rosalind A Eeles; Douglas F Easton; Daniela Seminara; Christopher I Amos
Journal:  Hum Mol Genet       Date:  2015-10-19       Impact factor: 6.150

Review 4.  Genetically Engineered Mouse Models of Prostate Cancer in the Postgenomic Era.

Authors:  Juan M Arriaga; Cory Abate-Shen
Journal:  Cold Spring Harb Perspect Med       Date:  2019-02-01       Impact factor: 6.915

5.  Timing of the loss of Pten protein determines disease severity in a mouse model of myeloid malignancy.

Authors:  Y Lucy Liu; Yan Yan; Cody Webster; Lijian Shao; Shelly Y Lensing; Hongyu Ni; Wei Feng; Natalia Colorado; Rupak Pathak; Zhifu Xiang; Martin Hauer-Jensen; Shaoguang Li; Daohong Zhou; Peter D Emanuel
Journal:  Blood       Date:  2016-01-13       Impact factor: 22.113

6.  The olfactory G protein-coupled receptor (Olfr-78/OR51E2) modulates the intestinal response to colitis.

Authors:  Kumar Kotlo; Arivarasu N Anbazhagan; Shubha Priyamvada; Dulari Jayawardena; Anoop Kumar; Yang Chen; Yinglin Xia; Patricia W Finn; David L Perkins; Pradeep K Dudeja; Brian T Layden
Journal:  Am J Physiol Cell Physiol       Date:  2020-01-08       Impact factor: 4.249

7.  The macrophage odorant receptor Olfr78 mediates the lactate-induced M2 phenotype of tumor-associated macrophages.

Authors:  Sri Murugan Poongkavithai Vadevoo; Gowri Rangaswamy Gunassekaran; ChaeEun Lee; NaHye Lee; Jiyoun Lee; Sehyun Chae; Jae-Yong Park; JaeHyung Koo; Byungheon Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2021-09-14       Impact factor: 11.205

8.  Rac1-mediated membrane raft localization of PI3K/p110β is required for its activation by GPCRs or PTEN loss.

Authors:  Onur Cizmecioglu; Jing Ni; Shaozhen Xie; Jean J Zhao; Thomas M Roberts
Journal:  Elife       Date:  2016-10-04       Impact factor: 8.140

9.  Inhibiting G protein βγ signaling blocks prostate cancer progression and enhances the efficacy of paclitaxel.

Authors:  Prakash Paudyal; Qing Xie; Prasanna Kuma Vaddi; Michael D Henry; Songhai Chen
Journal:  Oncotarget       Date:  2017-05-30

10.  JARID2 promotes invasion and metastasis of hepatocellular carcinoma by facilitating epithelial-mesenchymal transition through PTEN/AKT signaling.

Authors:  Xiong Lei; Jiang-Feng Xu; Rui-Min Chang; Feng Fang; Chao-Hui Zuo; Lian-Yue Yang
Journal:  Oncotarget       Date:  2016-06-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.